Solid Biosciences Inc.
NASDAQ:SLDB · NASDAQ Global Select
+$0.27 today
Vol 11.08M · Avg 1.39M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SLDB · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$191.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.95, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 -100.0% | $8.1M -40.6% | $13.6M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.6M -33.4% | $2.5M -4.9% | $2.6M | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$1.6M +33.4% | -$2.5M +4.9% | -$2.6M -131.9% | $8.1M -40.6% | $13.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $140.3M +45.5% | $96.4M +25.9% | $76.6M -2.4% | $78.4M +33.5% | $58.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $38.9M +16.8% | $33.3M +20.0% | $27.8M -4.1% | $28.9M +6.7% | $27.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $177.6M +39.5% | $127.3M +25.1% | $101.7M -11.2% | $114.5M +33.4% | $85.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.6M -33.4% | $2.5M -4.9% | $2.6M +7.2% | $2.4M -18.8% | $3.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$172.7M -41.7% | -$121.9M -30.5% | -$93.4M +3.5% | -$96.9M -39.9% | -$69.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | -1196.8% -688.5pp | -508.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$179.2M -38.1% | -$129.7M -24.4% | -$104.3M +2.0% | -$106.5M -47.3% | -$72.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | -1315.2% -784.7pp | -530.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $9.9M +4.6% | $9.5M +32.6% | $7.1M +173.0% | $2.6M +3987.5% | $64.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $340.0K | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $4.9M -3.0% | $5.0M -39.4% | $8.3M -59.5% | $20.5M +30916.7% | $66.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$174.3M -39.8% | -$124.7M -29.9% | -$96.0M -11.7% | -$86.0M -19.1% | -$72.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | -1062.3% -532.3pp | -530.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$174.3M -39.8% | -$124.7M -29.9% | -$96.0M -11.7% | -$86.0M -19.1% | -$72.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | -1062.3% -532.3pp | -530.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +35.0% | -$3 +36.6% | -$5 +52.2% | -$10 +0.4% | -$10 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +35.0% | -$3 +36.6% | -$5 +52.2% | -$10 +0.4% | -$10 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $87.5M +114.4% | $40.8M +105.3% | $19.9M +133.6% | $8.5M +19.6% | $7.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $87.5M +114.4% | $40.8M +105.3% | $19.9M +133.6% | $8.5M +19.6% | $7.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$851.27M
Design Therapeutics, Inc.
NASDAQ:DSGN
$761.35M
Annexon, Inc.
NASDAQ:ANNX
$586.27M
Autolus Therapeutics plc
NASDAQ:AUTL
$407.23M
Aura Biosciences, Inc.
NASDAQ:AURA
$399.32M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$350.51M
Benitec Biopharma Inc.
NASDAQ:BNTC
$314.31M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$272.37M
Quantum-Si incorporated
NASDAQ:QSI
$191.51M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SLDB generate?
Solid Biosciences Inc. (SLDB) reported $0.00 of revenue in fiscal 2025.
Is SLDB profitable?
Solid Biosciences Inc. (SLDB) reported -$174,325,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.